Fresenius Medical Care: A New CEO Inherits a Bigger TDAPA Cliff
Shervin Korangy’s first call narrows 2026 guidance, sizes a EUR300–350 million 2027 headwind, and admits patient inflow is only stabilizing—not growing.
FMS · Earnings Call · 2026-11-03
A Handoff Call, Not a Victory Lap
Fresenius Medical Care’s third-quarter call was always going to be about the handoff. Shervin Korangy, three weeks into the CEO job, opened by acknowledging the obvious: “It’s been just three weeks since I stepped into the role” — Shervin Korangy, Chief Executive Officer (CEO) · 2026-11-03. He comes from the Supervisory Board, which is why that phrase topped the company’s keyword stack this quarter even before the numbers did. The Street wanted a strategic reveal; he offered a process. “We are proceeding with urgency, yet I appreciate a little bit of patience” — Shervin Korangy, Chief Executive Officer (CEO) · 2026-11-03, he said, before promising a fuller vision around JPMorgan and the first half of 2027.
That patience may be tested. The quarter itself was broadly stable—revenue flat at constant currency, operating income excluding special items down 6%, margin 11%—but the forward math got worse. Management narrowed 2026 operating income growth to “flat to a negative mid-single-digit” rate, the lower half of its prior range. The culprit is not a demand shock. It is the slow-motion expiration of TDAPA headwind economics, plus inflation that is running hotter than the company’s own guardrails.
The TDAPA Cliff Is Bigger Than the Street Thought
The most important number on the call was not in the quarter; it was the 2027 bridge. CFO Martin Fischer said the company expects “an operating income headwind for 2027 between EUR 300 million and EUR 350 million” — Martin Fischer, Chief Financial Officer (CFO) · 2026-11-03 from TDAPA-related expiries. That is a large number, and it landed as a surprise. Analyst Graham Doyle pushed back almost immediately: “It just seems a lot larger than I think any of us were thinking” — Graham Doyle, Analyst · 2026-11-03. Fischer confirmed it was for the overall company, not just the pharma business.
We do expect an operating income headwind for 2027 between EUR 300 million and EUR 350 million based on the expiry that are TDAPA-related.
The tension is that this was not wholly untelegraphed. In August, then-CEO Helen Giza said the significant headwind from TDAPA roll-off was the “bigger moving bucket for 2027,” but she declined to size it: “I am not going to get into the moving pieces of 2027 guidance in August of ’26” — Helen Giza, Chief Financial Officer · 2026-08-04. Earlier, in February, Fischer had framed the 2026 TDAPA contribution as roughly EUR100 million staying in the business, with a reduction “bigger than EUR100 million from ’25 to ’26.” The new EUR300–350 million number is the market’s first clean look at the cliff—and it is steeper than expected. The keyword TDAPA headwind is not new for FMS, but the magnitude is.
Inflation adds a second squeeze. Fischer now expects the group to exceed the top end of its prior EUR300 million inflation headwind range, driven by higher oil and gas prices and Middle East-related logistics costs in Care Enablement. That is a change from the first-quarter language, when he said the company was “tracking in line with our assumptions on the inflation side” — Martin Fischer, Executive, likely CFO or similar financial leadership · 2026-05-05. The keyword inflationary pressure has moved from background risk to explicit guidance headwind.
Patient Inflow: Stabilization Is Not Growth
The operational story remains U.S. dialysis volumes. Same-market treatment growth in the U.S. fell 1.1% in the quarter, and management still expects about a 0.9% decline for the full year. The good news is that patient inflow stopped deteriorating: “patient inflow in the third quarter started to stabilize to a similar level as the prior year quarter” — Martin Fischer, Chief Financial Officer (CFO) · 2026-11-03. But stabilization is not recovery. Fischer was explicit that the company is missing the “accumulation effect” of patients lost in the first seven months of the year, so the same-market number will take time to turn.
This is a recurring FMS theme with a new tone. In the second quarter, Giza admitted the problem was internal: “it’s clear now that we have an operational miss, specifically in the business development approach” — Helen Giza, Chief Financial Officer · 2026-08-04. Management then promised fixes in referral relationships and local market execution. The third quarter shows those fixes are stabilizing the funnel, but not yet bending it. Korangy’s framing is more sober than his predecessor’s: “you need to think about it in a multi-quarter perspective” — Shervin Korangy, Chief Executive Officer (CEO) · 2026-11-03. That is the right operational read, but it also means 2027 starts with a volume hole.
There is a subtle shift in language, too. “Clinic closure” was a top keyword in the second-quarter call; it has fallen out of the top 30 this quarter. The new CEO’s emphasis is on “portfolio” and “prioritization,” not another round of cost-driven closures. That may be wise—closing clinics helped margins but also contributed to volume leakage—but it leaves the cost offset less obvious. Korangy’s answer to the investment-versus-cost-cutting debate was a philosophy, not a plan: “Cost cutting for just improvement of margins and/or expansion of profit is narrow” — Shervin Korangy, Chief Executive Officer (CEO) · 2026-11-03. The keyword Cost cutting is now near the top of FMS’s own stack, which is the language of defense, not offense.
The DaVita Dialyzer Question and the HV-HDF Bright Spot
The competitive question of the call came from BNPP’s Hugo Solvet: DaVita has signaled a transition to MCO dialyzers by November. Fischer would not disclose contract specifics, but he did not dismiss the risk: “that would lead to a certain headwind that we have for the dialyzer piece” — Martin Fischer, Chief Financial Officer (CFO) · 2026-11-03. The rest of the Care Enablement relationship—machines, consumables—may hold, but the dialyzer piece is exposed. Korangy added that MCO is “not a new technology,” approved in Europe for close to a decade and in the U.S. for over half a decade, which is a polite way of saying the competitive standard is shifting.
This is where the global context matters. DaVita’s own recent report led with expanded HD and kidney failure, the same clinical and competitive turf FMS is defending. The global keyword set also flagged kidney failure as a top-75 market theme this quarter, a reminder that dialysis is a two-player public market in the U.S. and the competitive read-through is direct.
The offset is the HV HDF rollout. FMS has converted 348 clinics, or 14% of its U.S. base, installed roughly 9,000 machines—about 16% of the install base—and is on track for 20% by year-end. It has performed around 300,000 high-volume HDF treatments, about 1.3% of total treatments. Management calls the 5008X CAREsystem a standard of care story, and the early feedback is positive. But external sales are being deliberately subordinated to FMS’s own clinics, so HV-HDF is a 2027–2028 margin and mortality lever, not a 2027 earnings plug.
What Changed, What Didn’t
What changed: a new CEO with a Supervisory Board pedigree, a lower 2026 guidance range, a bigger 2027 TDAPA cliff, and a fresh acknowledgment that inflation is above the prior band. What did not: the U.S. volume problem is still a recovery story, not a growth story; the DaVita dialyzer risk is real but unsized; and capital allocation remains pinned to the lower end of the leverage range, with a EUR1 billion buyback and net leverage at 2.6x. Korangy’s return on capital language is the right frame, but the first call was long on process and short on numbers.
The setup is now a classic “show-me” transition: investors must underwrite a 2027 earnings trough before they get the new CEO’s strategic plan. The bull case rests on HV-HDF, FME25+ savings, and a volume bottom. The bear case rests on a EUR300–350 million TDAPA hole, a possible DaVita dialyzer loss, and inflation that is no longer behaving. Korangy has bought himself a quarter or two of patience. The math has not.